We thank Dr Sanjay for his comments on our paper and wish to clarify that in our study there were no recurrences in the placebo or polyhexamethylene biguanide (PHMB) groups. The mean duration of follow-up for the patients who were included in this study was 12.2 ± 8.7 days (median: 9, range: 3–51). Of the 12 eyes where steroid was used, 8 eyes had features of mild uveitis. These eyes presented with mild anterior chamber reaction and fine nonpigmented fresh keratic precipitates. There was no immune-mediated endotheleitis. None of the patients in the study required additional systemic albendazole. Moreover, it was not included in our study protocol.

The patients in the placebo group who were switched to PHMB had a similar final outcome compared to those who were initially on PHMB. Out of 4 patients who were switched, 2 had a visual outcome of 20/20, one had visual acuity of 20/30 improving to 20/20, and the fourth patient had a visual acuity of 20/120 due to cataract.

As suggested, we agree that the role of fluoroquinolones remains to be investigated.